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Introduction: We previously reported that low ratio of osteoprotegerin (OPG) to tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) was associated with Disease Activity Score in 28 joints (DAS28) remission at
6 months in patients with early rheumatoid arthritis (RA). Here, we aimed to evaluate the value of baseline
OPG/TRAIL ratio in predicting clinical and radiological outcomes in patients with early RA in the ESPOIR cohort.
Methods: OPG and TRAIL serum concentrations were assessed in the ESPOIR cohort patients. Patients with
definite RA were included in this study. Patients were excluded if they had high erosion score at baseline
(>90th percentile) or received biological therapy during the first 2 years of follow-up. Data were analyzed by
univariate analysis and multivariate logistic regression to predict 1-year DAS28 remission and 2-year radiographic
disease progression.
Results: On univariate analysis of 399 patients, OPG/TRAIL ratio at baseline was significantly lower in patients with than
without remission at 1 year (p = 0.015). On multivariate logistic regression including age, gender, body mass index and
DAS28, low OPG/TRAIL ratio was independently associated with remission at 1 year (odds ratio 1.68 [95 % confidence
interval 1.01–2.79]). On univariate analysis, high OPG/TRAIL ratio at baseline was associated with rapid progression of
erosion at 2 years (p = 0.041), and on multivariate logistic regression including age, anti-citrullinated protein antibody
positivity and C-reactive protein level, OPG/TRAIL ratio independently predicted rapid progression of erosion at 2 years.
Conclusions: OPG/TRAIL ratio at baseline was an independent predictor of 1-year remission and 2-year rapid progression
of erosion for patients with early rheumatoid arthritis. Thus, OPG/TRAIL ratio could be included in matrix prediction scores
to predict rapid radiographic progression. Further confirmation in an independent cohort is warranted.Introduction
Rheumatoid arthritis (RA) is a frequent autoimmune
disease, with a prevalence of 0.3 to 1 % worldwide.
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creativecommons.org/publicdomain/zero/1.0/or rituximab. Most patients primarily receive conven-
tional synthetic DMARDs because early intensive ther-
apy is not cost-effective [1]. However, a subgroup of
patients is at risk of radiographic disease progression
and has a low chance of achieving remission with conven-
tional synthetic DMARDs. These patients usually have high
levels of rheumatoid factor (RF) and high titers of anti-
citrullinated protein antibodies (ACPA), very high disease
activity and/or early radiographic joint damage [2].
Biomarkers beside these usual prognostic factors that
could identify patients at risk of radiographic progres-
sion and inadequate response to conventional syntheticicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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andameliorating the disease course in this targeted
population.
The cytokine tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) was initially described for its
ability to trigger cell death in a somewhat tumor-selective
manner. The TRAIL system is probably one of the most
complex members of the TNF family because of the large
number of receptors to which TRAIL can bind but also
because of the signaling pathways engaged. TRAIL can
interact with five different receptors: four membrane-
anchored receptors, TRAIL-R1 (DR4), -R2 (DR5), -R3
(DcR1) and -R4 (DcR2), and a soluble decoy receptor,
osteoprotegerin (OPG). Because of the diversity of TRAIL
receptors, multiple proprieties were described. TRAIL can
trigger apoptosis as well as proliferation and differentiation
depending on the cell type (reviewed in [3]). The first
report linking TRAIL with arthritis came from a mouse
study with a collagen-induced arthritis model [4, 5].
Studies investigating the role of TRAIL in RA mostly
focused on the therapeutic potential of TRAIL, especially
RA fibroblast-like synoviocytes (FLSs), because hyperplas-
tic RA FLSs have tumor-like features [6]. However, we
found that TRAIL induces apoptosis only in a subset of
RA FLSs and induces proliferation in surviving cells [7].
This finding challenged the use of TRAIL for targeting
hyperproliferative FLSs, and despite numerous reports
describing the effect of TRAIL on RA, its role in patho-
genesis is still not fully clarified [3].
OPG is also a decoy receptor for receptor activator of
nuclear factor B ligand (RANKL) [8]. OPG has been
demonstrated to be involved in bone erosion and bone
remodeling [9], and it was recently shown that genetic
variant in OPG is associated with progression of joint
destruction in RA [10]. RANKL and its receptor RANK
play a key role in regulating osteoclastogenesis. Indeed,
RANKL stimulates differentiation of osteoclasts via RANK
signaling. Competing with RANK for RANKL binding,
OPG is able to prevent osteoclastogenesis activity [8, 11].
In addition, OPG inhibits TRAIL-induced apoptosis by
binding to TRAIL [11]. Conversely, TRAIL blocks OPG-
mediated inhibition of osteoclastogenesis. Thus, OPG and
TRAIL may inhibit their respective biological functions.
Because the role of TRAIL in patients with RA was not
well established, we performed a prospective pilot study to
measure serum levels of OPG and TRAIL in patients with
early RA (<2 years) and investigated their association with
various clinical parameters [12]. Low OPG/TRAIL ratio at
baseline was associated with remission (Disease Activity
Score in 28 joints [DAS28] <2.6) at 6 months, which sug-
gests that the ratio of OPG to TRAIL might be a predict-
ive factor for remission in early RA [12]. In the present
study, we evaluated the independent value of OPG/TRAIL
ratio in predicting DAS28 remission at 1 year according tothe European League Against Rheumatism (EULAR)
criteria and rapid radiographic disease progression (at 2
years) to identify patients who would benefit from early
intensive therapy. Patients were from a large and well-
documented cohort of early RA, the Etude et Suivi des
POlyarthrites Indifférenciées Récentes (ESPOIR) cohort.
Methods
ESPOIR cohort
The ESPOIR cohort is a prospective multicenter observa-
tional study of patients 18–70 years old who have early
arthritis under the umbrella of the French Society for
Rheumatology. The protocol of the ESPOIR cohort study
was approved in July 2002 by the ethics committee of
Montpellier University (number 020307). All patients gave
their signed informed consent to be included in the study.
Patients were recruited if they had inflammatory arth-
ritis in at least two swollen joints lasting for 6 weeks to
6 months, with the potential to develop into RA. The
population and methods of the ESPOIR cohort are de-
tailed elsewhere [13]. Treatment by rheumatologists
followed the standard of care and patients were followed
every 6 months during the first 2 years, then every year.
At baseline and each visit, clinical and biological data
relevant to the management of early arthritis were re-
corded. Patients underwent radiography of the hand,
wrist (face) and foot (face and oblique) at baseline, then
at 1 and 2 years. X-ray films were scored by use of the
van der Heijde-modified Sharp score (mSharp score) [14]
for radiographic disease progression.
The ESPOIR cohort included 813 patients. In this
ancillary study, we included patients fulfilling the
American College of Rheumatology-European League
Against Rheumatism (ACR-EULAR) 2010 criteria for
RA at inclusion. We excluded patients with a history
of lymphoma and neoplasia (n = 13) because of a
known relation between TRAIL and tumor genesis and
those with the highest erosion scores (mSharp erosion
score >90th percentile; n = 62). Indeed, radiographic erosion
at baseline is a well-characterized factor of further radio-
graphic progression [15], and the EULAR task force recom-
mended prompt use of biological therapy in these rare
cases [1]. The 90th percentile of mSharp erosion score cor-
responded to 4 points. We also excluded patients who re-
ceived biological therapy in the first 2 years (n = 121)
because it strongly affects radiographic disease progression.
Serum assays
Blood samples were taken for investigation of C-reactive
protein (CRP) level and erythrocyte sedimentation rate
(ESR). Serum samples were collected at enrollment and
immediately stored at -80 °C in a single biologic resource
centre. A central laboratory determined levels of anti-
citrullinated cyclic peptide (anti-CCP) antibodies (anti-
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U/ml) and rheumatoid factor (RF) (Ménarini France,
Rungis Cedex, France; positive >9 IU/ml) with enzyme-
linked immunosorbent assay (ELISA).Determination of OPG and TRAIL serum levels
OPG and TRAIL serum levels were measured by using
commercially available ELISA kits (human OPG Quanti-
kine ELISA kit, R&D Systems, Minneapolis, MN, USA; and
human TRAIL ELISA kit, Diaclone, Besançon, France) and
expressed in pg/ml. RF depletion did not alter results for
OPG or TRAIL concentrations (data not shown).Radiographic disease progression
Rapid radiographic progression was defined by at least a
5 point per year increase in total mSharp score, which
corresponds to a 10-point increase at 2 years. This cutoff
has been previously used [16, 17]. Because erosion and
joint-space narrowing are almost similar to total mSharp
score, we defined rapid progression of erosion or rapid
progression of joint-space narrowing as at least a 5-point
increase in erosion score or joint-space narrowing score
at 2 years.Table 1 Baseline characteristics of all patients with rheumatoid
arthritis (RA) responding to 2010 ACR-EULAR criteria included in
the ESPOIR cohort and RA patients included in this study
Characteristics All RA patients
(n = 641)
Patients in the study
(n = 399)
Age (years) 48.1 ± 12.6 48.4 ± 11.9
Female (%) 78 81
Body mass index (kg/m2) 25.1 ± 4.7 25.2 ± 4.6




DAS28(ESR)-4v 5.4 ± 1.2 5.3 ± 1.2
HAQ score 1.0 ± 0.7 1.0 ± 0.7
Total mSharp score 5.29 ± 7.5 3.77 ± 4.4
Steroid use (%) 13 14
Data are mean ± SD or percentage
RA rheumatoid arthritis, DAS28(ESR)-4v Disease Activity Score in 28 joints,
calculated with erythrocyte sedimentation rate and four values, HAQ Health
Assessment Questionnaire, mSharp score van der Heijde-modified Sharp scoreStatistical analysis
The values of OPG and TRAIL showed a skewed dis-
tribution, and normality was obtained after natural
logarithmic (log) transformation. OPG to TRAIL ratio
(OPG/TRAIL ratio) was used as previously described
[12]. Student t and chi-square tests were used to compare
baseline characteristics for 1) patients with or without
DAS28 remission at 1 year and 2) patients with or without
rapid radiographic disease progression at 2 years (total
mSharp score increase ≥10 or erosion score ≥5 or joint-
space narrowing score ≥5). Odds ratios (ORs) were
obtained by logistic regression, with 1-year DAS28 re-
mission and 2-year rapid radiographic progression as
dependent variables. All covariates associated at the
20 % level (p <0.20) on univariate analysis were in-
cluded in the multivariate logistic regression model as
potential confounders and selected by stepwise multiple re-
gression. A receiver-operating characteristic (ROC) curve
was plotted to identify a cutoff value of OPG/TRAIL ratio
associated with 2-year rapid radiographic progression [18].
True-positive patients were those with high OPG/TRAIL
ratio and rapid radiographic progression, and true-negative
patients were those with low ratio OPG/TRAIL ratio and
without rapid radiographic progression. The best possible
OPG/TRAIL ratio threshold was determined by using the
highest Youden Index [(specificity + sensitivity) − 1] [19].
Statistical analysis involved use of PASW v18 (SPSS Inc.,
Chicago, IL, USA).Results
Patient characteristics
The characteristics of all RA patients included in ESPOIR
cohort (fulfilling ACR-EULAR 2010 criteria) and the 399
patients included in this study are in Table 1. Briefly,
patients included in this study and all ESPOIR cohort
patients were similar except for total mSharp score be-
cause we excluded patients with the highest erosion score
at baseline.
Age, gender, DAS28 and OPG/TRAIL ratio are associated
with DAS28 remission at 1 year
On univariate analysis, age, gender, DAS28 and OPG/
TRAIL ratio at baseline differed between patients with
and without DAS28 remission at 1 year (Table 2). Pa-
tients in remission were younger, less often female and
had lower DAS28 at baseline than patients with active
disease at 1 year. Moreover, body mass index and ESR
were lower but not significantly for patients in remission
than with active disease at 1 year (p = 0.06 and p = 0.07,
respectively) (Table 2). Low OPG/TRAIL ratio (logOPG/
TRAIL ratio <25th percentile) was associated with remis-
sion at 1 year (OR = 1.76 [95 % confidence interval (95 %
CI) 1.11–2.81]) (Table 2). This association was mainly ex-
plained by OPG. Indeed, low OPG (Q <25e percentile ver-
sus ≥25e percentile) was associated with 1 year remission
(OR = 1.76 [1.10–2.81], p = 0.017) whereas TRAIL was
not. Of note, OPG/TRAIL ratio correlated with DAS28 at
baseline (r = 0.10; p = 0.04).
Low OPG/TRAIL ratio independently predicts DAS28
remission at 1 year
On multivariate logistic regression, female sex was asso-
ciated with DAS28 remission at 1 year (OR = 0.49 [95 %
Table 2 Association of main baseline characteristics of RA patients with DAS28 remission at 1 year (univariate analysis)
DAS28 remission at 1 year P value OR (95 % CI)
yes no
Age (years) 46.5 ± 12.6 49.6 ± 11.3 0.01 0.98 (0.96–0.99)
Females (%) 75 86 0.01 0.49 (0.29–0.82)
Body mass index (kg/m2) 24.6 ± 4.4 25.5 ± 4.6 0.06 0.96 (0.91–1.00)
Rheumatoid factor positivity (%) 51.3 51.1 0.97 1.01 (0.67–1.51)
Anti-citrullinated protein antibody positivity (%) 46.8 43.7 0.55 1.14 (0.75–1.71)
mSharp score 3.53 ± 4.02 3.75 ± 4.49 0.61 0.99 (0.94–1.04)
DAS28(ESR)-4v 4.98 ± 1.18 5.49 ± 1.16 0.00 0.69 (0.57–0.823)
logCRP (log-mg.l−1) 1.01 ± 0.47 1.03 ± 0.49 0.73 0.93 (0.59–1.44)
ESR 25 ± 22 29 ± 24 0.07 0.99 (0.98–1.00)
Steroids (%) 87.8 85.6 0.53 1.21 (0.66–2.22)
Use of cDMARD (%) 78.7 79.6 0.83 1.95 (0.57–1.57)
logOPG/TRAIL ratio Q <25 (%) 31.4 20.6 1.76 (1.11–2.81)a*
logOPG/TRAIL ratio Q25–75 (%) 41.7 51.7 0.015
logOPG/TRAIL ratio Q >75 (%) 26.9 23.7 1.19 (0.74–1.89)b
Data are mean ± SD (median) or percentage. Student t test for continuous variables and chi-square test for categorical variables
RA rheumatoid arthritis, DAS28 Disease Activity Score in 28 joints, OR odds ratio, 95 % CI, 95 % confidence interval, cDMARD conventional disease-modifying
anti-rheumatic drug (used at least at two visits), CRP C-reactive protein, DAS28(ESR)-4v Disease Activity Score in 28 joints, calculated with erythrocyte sedimentation
rate (ESR) and four values, mSharp score van der Heijde-modified Sharp score, OPG osteoprotegerin, TRAIL tumor necrosis factor-related apoptosis-inducing ligand,
Q <25 quartile <25th percentile, corresponding to 0.932, Q >75 quartile >75th percentile, corresponding to 1.039
*p <0.05 p value for comparison of aQ <25th versus ≥25th percentile and bQ >75th versus ≤75th percentile
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[0.59–0.86]). ESR was not significantly associated (p =
0.922) (Table 3). Low logOPG/TRAIL ratio (<25th per-
centile) was associated with DAS28 remission at 1 year,
independent of other factors (OR = 1.68 [1.01–2.79])
(Table 3). This association was mainly explained by
OPG. Indeed, low OPG (Q <25e percentile versus ≥25e
percentile) was associated with 1 year remission in
multivariate model (OR = 1.67 [1.01–2.77]; p = 0.047)
whereas TRAIL was not.
Of note, OPG/TRAIL ratio at baseline was also associ-
ated with DAS28 remission at year 2, although not signifi-
cantly, in the univariate (p = 0.09) and multivariate model
(p = 0.082; OR = 1.54 [0.95–2.59]).Table 3 Multivariate logistic regression analysis of factors
predicting DAS28 remission at 1 year
Variable OR (95 % CI) P value
Age (per year increase) 0.98 (0.96–1.00) 0.086
Female (versus male) 0.49 (0.28–0.86) 0.013
Body mass index (per kg.m-2) 0.95 (0.90–1.00) 0.057
DAS28 (per unit increase) 0.71 (0.59–0.86) 0.001
logOPG/TRAIL ratio Q <25 vs ≥25
(per category increase)
1.68 (1.01–2.79) 0.045
ESR was excluded from the model due to non-significance (p = 0.922)
DAS28 Disease Activity Score in 28 joints, OR odds ratio, 95 % CI, 95 %
confidence interval, OPG osteoprotegerin, TRAIL tumor necrosis factor-related
apoptosis-inducing ligandRF, anti-CCP antibodies, CRP level, ESR and OPG/TRAIL
ratio are associated with rapid radiographic disease
progression at 2 years
On univariate analysis, RF and ACPA positivity as well
as high CRP level and ESR at baseline were associated
with rapid progression of total mSharp score at 2 years
(Δtotal mSharp score ≥10, Δerosion mSharp score ≥5 or
Δjoint-space narrowing mSharp score ≥5) (Table 4).
Concerning total mSharp score, older age was associated
with rapid radiographic progression. High OPG/TRAIL
ratio (logOPG/TRAIL >75th percentile) was associated
with rapid erosion progression (OR = 2.419 [95 % CI
1.136–5.152]) (Table 4).
This association was mainly explained by TRAIL with
low TRAIL (Q <25th percentile versus Q ≥25th) associated
with rapid erosion progression (OR = 2.76 [1.30–5.84];
p = 0.008) whereas OPG was not associated with radio-
graphic progression.
OPG/TRAIL ratio is an independent predictor of rapid
erosion progression (change in erosion mSharp score >5
at 2 years)
On multivariate analysis, RF, ESR and total Sharp score
at baseline were not significantly associated with rapid
erosion progression (p = 0.55, p = 0.21, p = 0.77, re-
spectively) and were excluded from the analysis. Of note,
total mSharp score was strongly associated with radio-
graphic progression in all ESPOIR RA patients (p <0.001).
Thus, excluding patients with the highest erosion scores at
Table 4 Association of main baseline characteristics of RA patients with rapid radiographic progression at 2 years (univariate analysis)
ΔM24–M0 total
mSharp >10
P value OR (95 % CI) ΔM24–M0 erosion
mSharp > 5
P value OR (95 % CI) ΔM24–M0 joint-space
narrowing mSharp >5
P value OR (95 % CI)
Yes No Yes No Yes No
Age 51.5 ± 10.7 48.2 ± 11.8 0.059 1.03 (0.99–1.05) 51.8 ± 8.9 48.4 ± 11.8 0.108 1.03 (0.99–1.06) 49.4 ± 11.4 48.4 ± 11.7 0.471 1.01 (0.98–1.03)
Female (%) 84.6 81.1 0.543 0.78 (0.35–1.74) 87.5 81.0 0.367 1.64 (0.56–4.83) 83.5 80.9 0.571 1.19 (0.65–2.20)
BMI 25.9 ± 4.9 25.3 ± 4.6 0.245 1.04 (0.98–1.10) 25.1 ± 4.9 25.3 ± 4.6 0.866 0.99 (0.927–1.08) 25.6 ± 4.7 25.2 ± 4.6 0.447 1.02 (0.97–1.07)
RF (%) 69.2 48.2 0.005 2.42 (1.29–4.53) 78.1 41.7 0.005 3.14 (1.37–7.18) 64.9 46.3 0.002 2.15 (1.33–3.47)
ACPA (%) 65.4 41.5 0.001 2.67 (1.45–4.92) 75.0 48.9 0.005 5.0 (2.106–11.872) 59.8 39.6 0.001 2.271 (1.418–3.635)
Total mSharp score 4.0 ± 4.8 3.7 ± 4.4 0.644 1.10 (0.95–1.08) 4.5 ± 5.0 3.7 ± 4.4 0.341 1.04 (0.96–1.12) 3.8 ± 4.8 3.7 ± 4.3 0.837 1.01 (0.95–1.06)
DAS28(ESR)-4v 5.5 ± 1.4 5.3 ± 1.1 0.211 1.2 (0.9–1.5) 5.5 ± 1.5 5.3 ± 1.2 0.331 1.16 (0.86–1.59) 5.3 ± 1.3 5.3 ± 1.1 0.784 1.03 (0.84–1.25)
logCRP level 1.25 ± 0.51 0.98 ± 0.46 0.000 3.3 (1.8–6.3) 1.25 ± 0.49 1.00 ± 0.47 0.004 1.01 (1.00–1.02) 1.16 ± 0.47 0.96 ± 0.46 0.001 2.414(1.445–4.03)
ESR 35 ± 26 28 ± 24 0.009 1.01 (1.00–1.02) 36 ± 29 28 ± 24 0.016 1.01 (1.00–1.02) 32 ± 25 26 ± 21 0.030 1.01 (1.00–1.02)
Steroid use (%) 19.2 13.4 0.264 0.651 (0.305–1.390) 8.0 13.4 0.413 1.66 (0.49–5.65) 83.5 86.6 0.455 0.785 (0.416–1.483)
cDMARD use (%) 89.6 82.2 0.210 1.86 (0.71–4.91) 85.2 83 0.774 1.18 (0.39–3.53) 90.2 80.8 0.041 2.19 (1.03–4.64)
logOPG/TRAIL ratio
Q <25 (%)
23.5 25.6 0.894 (0.447–1.787)a 12.9 26.4 0.412 (0.140–1.210)a 26.0 25.1 1.051 (0.619–1.785)a
LogGPG/TRAIL ratio
Q25–75 (%)
47.1 50.6 0.685 45.2 50.6 0.041 53.1 49.1 0.614
logOPG/TRAIL ratio
Q >75 (%)
29.4 23.8 1.335 (0.695–2.568)b 41.9 23.0 2.419 (1.136–5.152)b* 20.8 25.8 0.757 (0.432–1.325)b
Data are mean ± SD (median) or percentage. Significant values are in bold
RA rheumatoid arthritis, M month, mSharp score van der Heijde-modified Sharp score, OR odds ratio, 95 % CI, 95 % confidence interval, BMI body mass index, RF rheumatoid factor, ACPA anti-citrullinated protein
antibodies, DAS28(ESR)-4v Disease Activity Score in 28 joints, calculated with erythrocyte sedimentation rate (ESR) and four values, CRP C-reactive protein, cDMARD conventional disease-modifying anti-rheumatic drug
(used at least at two visits),, OPG osteoprotegerin, TRAIL tumor necrosis factor-related apoptosis-inducing ligand, Q <25 quartile <25th percentile, Q >75 quartile >75th percentile














Fig. 1 Frequency of rapid progression of erosion for each quartile
increase of OPG/TRAIL ratio. Frequency of rapid progression of
erosion (change in erosion mSharp score >5 at 2 years) in patients
with rheumatoid arthritis at 2 years by baseline logarithmic ratio of
quartiles of osteoprotegerin to tumor necrosis factor-related
apoptosis-inducing ligand (logOPG/TRAIL) is shown
Audo et al. Arthritis Research & Therapy  (2015) 17:193 Page 6 of 8baseline, as we did in this study, removed any of the total
mSharp score predictive value for rapid radiographic
progression. ACPA positivity was highly associated with
risk of rapid erosion progression (OR = 3.95 [95 % CI
1.26–12.4]) (Table 5). LogOPG/TRAIL ratio was inde-
pendently associated with risk of rapid erosion progres-
sion (OR = 1.90 [1.03–3.52]) for each quartile increase
(Table 5 and Fig. 1). This association was mainly ex-
plained by TRAIL with low TRAIL (Q <25th percentile
versus Q ≥25th) associated with rapid erosion progres-
sion (OR = 2.57 [1.14–5.79]; p = 0.022) whereas OPG
was not associated with radiographic progression in
multivariate analysis.
Of note, on multivariate logistic regression, age, ACPA
positivity and CRP level but not ESR, RF positivity and
logOPG/TRAIL ratio were associated with rapid radio-
graphic progression (total mSharp score).
Using ROC analysis, we determined that OPG/TRAIL
ratio ≥1.198 was the best threshold to predict rapid
radiographic progression (Fig. 2), with sensitivity 65 %
and specificity 73 % and area under the ROC curve
0.65 ± 0.05 (p = 0.005).
Discussion
We confirmed in a large cohort of early rheumatoid
arthritis that low OPG/TRAIL ratio is associated with
DAS28 remission at 1 year. In addition, high OPG/TRAIL
ratio could predict rapid progression of erosion at 2 years
independent of factors known to be associated with radio-
graphic disease progression.
In this study, OPG level at baseline was correlated
with disease activity and determined the association be-
tween OPG/TRAIL ratio and 1 year remission. OPG has
proinflammatory effects that could be mediated by acti-
vation of the nuclear factor kappa B (NF-kB) pathway
[20, 21], which suggests that OPG plays a role in RA
inflammation. Because we found high OPG/TRAIL
ratio associated with risk of rapid erosion progression
mainly due to low TRAIL values, our results favor a
protective effect of TRAIL on bone erosion in RA. This
finding could be surprising because TRAIL neutralizesTable 5 Multivariate logistic regression analysis of factors
predicting rapid erosion progression (ΔM24–M0 erosion mSharp
score >5)
Variable OR (95 % CI) P value
Age (per year increase) 1.06 (0.99–1.07) 0.076
ACPA positivity (versus negativity 3.95 (1.26–12.44) 0.019
logCRP (per log-unit) 2.01 (0.83–4.87) 0.121
logOPG/TRAIL ratio (per category increase) 1.90 (1.03–3.52) 0.041
M month, mSharp score van der Heijde-modified Sharp score, OR odds ratio, 95 %
CI 95 % confidence interval, ACPA anti-citrullinated protein antibodies, OPG
osteoprotegerin, TRAIL tumor necrosis factor-related apoptosis-inducing ligand
Significant values are in boldthe OPG-inhibitory effect on osteoclastogenesis. How-
ever, TRAIL can also have a direct effect on osteoblasts
and osteoclasts [3]. In vitro evidence suggests that
TRAIL acts on bone remodeling. Indeed, TRAIL-
induced apoptosis of osteoblasts differentiated from
peripheral blood mononuclear cells in vitro and blocked
the differentiation of osteoclasts [22–24]. Thus, in theFig. 2 Receiver operating characteristic (ROC) curve to determine
the best threshold for OPG/TRAIL ratio to predict rapid erosions.
Patients treated with biological therapy during the first 2 years and
with radiographic evidence of damage at baseline were excluded.
Osteoprotegerin to tumor necrosis factor-related apoptosis-inducing
ligand (OPG/TRAIL) ratio (both values expressed in pg/ml). The star
shows the 1.198 OPG/TRAIL ratio
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tiation, thus protecting against erosion.
In contrast, a few studies have investigated the effect
of TRAIL on human chondrocytes in vitro [25], which
suggests that TRAIL has a marginal impact on cartilage
structure. These in vitro observations could suggest that
TRAIL is more specifically associated with erosion than
joint-space narrowing.
Identifying patients at high risk of radiographic disease
progression is useful in daily practice for proposing more
intensive therapy. OPG/TRAIL ratio can predict rapid pro-
gression of erosion but not rapid radiographic progression
with total mSharp score. However, radiographic erosions
are the most important parameter predicting long-term
total mSharp score, better than joint-space narrowing [26].
The strength of this study is the large number of pa-
tients and its prospective design. One limitation is that
patients received treatment according to routine care
and not a standardized protocol. The evaluation of 2-year
radiographic progression was performed under different
therapeutics. Therefore, we cannot rule out the possibility
of treatment confounders. To partially control for this
confounding factor, we excluded patients who received
biological therapy during this period. In addition, the
relatively low sensitivity and specificity of OPG/TRAIL
ratio in predicting rapid progression of erosion, leaves
the possibility that our findings could be false positive.
A replication in an independent cohort will be warranted.
To predict the risk of rapid disease progression, some
groups proposed matrix prediction scores [15, 27]. How-
ever, these tools need to be constructed with the utmost
accuracy to predict rapid radiographic progression. Thus,
OPG/TRAIL ratio may be an interesting parameter for in-
clusion in a matrix.
Conclusions
In conclusion, we found high OPG/TRAIL ratio associ-
ated with lack of disease remission in RA and with rapid
progression of erosion. These results support a protective
role of TRAIL on bone, probably mediated by its effects
on osteoclast differentiation and apoptosis. Measuring
serum OPG and TRAIL level to calculate the OPG/TRAIL
ratio could help predict patients at high risk of radio-
graphic disease progression.
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